Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Diabetes drug indication extended

  • Comment

The European Commission has expanded the indication of the type 2 diabetes drug sitagliptin (Januvia).

The drug, a dipeptidyl peptidase-4 inhibitor, was previously approved for use with metformin when diet, exercise and metformin had failed to achieve adequate glycaemic control. The label expansion means it now be used in combination with a sulphonylurea or a sulphonyluria plus metformin, when the previous regimen plus lifestyle changes has failed to achieve adequate glycaemic control

The recommended dose is 100mg once daily, with or without food, for all adopted indications.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.